Blueshift Asset Management LLC Sells 22,718 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Blueshift Asset Management LLC cut its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 55.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,368 shares of the company's stock after selling 22,718 shares during the quarter. Blueshift Asset Management LLC's holdings in Teva Pharmaceutical Industries were worth $405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Stifel Financial Corp lifted its position in Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after purchasing an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its stake in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after buying an additional 33,277 shares during the period. Thrivent Financial for Lutherans raised its holdings in Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company's stock valued at $4,046,000 after buying an additional 40,218 shares during the last quarter. Sio Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $24,314,000. Finally, Pinnbrook Capital Management LP bought a new stake in Teva Pharmaceutical Industries in the 4th quarter worth $4,966,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Teva Pharmaceutical Industries Stock Up 0.5 %

TEVA traded up $0.08 during trading on Monday, reaching $16.18. The stock had a trading volume of 8,023,829 shares, compared to its average volume of 9,436,029. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock's 50 day moving average is $17.70 and its two-hundred day moving average is $18.19. The company has a market capitalization of $18.34 billion, a price-to-earnings ratio of -11.16, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

TEVA has been the subject of several recent analyst reports. Barclays lowered their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th. Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Finally, UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.